Corpus ID: 4861648

Promotion of corneal allograft survival with leflunomide.

  title={Promotion of corneal allograft survival with leflunomide.},
  author={Jerry Y. Niederkorn and Laura Smith Lang and J R Ross and J Mellon and Stella M Robertson},
  journal={Investigative ophthalmology \& visual science},
  volume={35 10},
PURPOSE The efficacy of the antirejection drug leflunomide was evaluated in a rat model of penetrating keratoplasty. METHODS Corneal grafts from inbred Lewis rats were transplanted orthotopically to inbred Wistar-Furth (WF) recipients. WF rats received either Leflunomide (HWA 486), the active metabolite of leflunomide (A77-1726A), or cyclosporin A, administered orally beginning 2 days before transplantation and continuing for 30 days thereafter. Graft survival was assessed clinically three… Expand
Leflunomide therapy following penetrating keratoplasty in the rat
It is suggested that LF when used alone is as effective as CSA in treating corneal allograft rejection in the rat, and when LF and CSA are combined they are more effective than either drug alone in the prolongation of allografted survival. Expand
FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation.
Long-term survival of hamster liver and heart xenografts in Lewis rats could be induced by a regimen of short-term FK506 in combination with Lef followed by FK505 monotherapy, and this reflects primarily a modification in the host immune response to the hamster graft. Expand
Efficacy of immunosuppressive drugs in islet xenotransplantation: leflunomide in combination with cyclosporine and mycophenolate mofetil prevents islet xenograft rejection in the pig-to-rat model.
Treatment with leflunomide (LEF), cyclosporine (CsA), mycophenolate mofetil (MMF), 15-deoxyspergualin, and rapamycin alone or in combination had an insufficient inhibitory effect on ICC xenograft rejection, but in animals treated with LEF+CsA, the rejection process was markedly inhibited. Expand
Recent developments in the pharmacological treatment and prevention of corneal graft rejection
This review discusses the limited data available whilst proposing newer therapies that have developed as a result of increased understanding of the immunobiology of corneal graft rejection and suggests that immunosuppressive therapy has not enjoyed the success seen in solid organ grafts. Expand
Corneal graft rejection.
Knowing the immunopathogenesis of graft rejection may allow a better understanding of the immunological process thus helping in its prevention, early detection and management. Expand
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review
The pharmacological and safety profile of LF is reviewed with a focus on the LF-induced hepatic injury from the perspective of pathophysiology and possible protective agents. Expand
Immunosuppressives in Uveitis and Ocular Inflammation
The goal of management is to suppress the sight-threatening ocular inflammation as soon as possible with a rapidly effective medication, usually using topical, systemic, and/or injected corticosteroids. Expand
Leflunomide interferes with pyrimidine nucleotide biosynthesis
Results indicate that inhibition of pyrimidine biosynthesis is responsible for the anti-proliferative effects of leflunomide. Expand
Immunreaktion nach perforierender Keratoplastik II. Prävention und Therapie
Eine verminderte Sensibilisierung des Empfängers durch reduzierte Antigendifferenz (“MHC-Matching”) oder eine pharmakologische Behandlung mit Modulation der afferenten und efferenten Immunantwort. Expand
Immunmodulation bei perforierender Keratoplastik
This review attempts to address some new concepts of tolerance induction following penetrating keratoplasty and the spectrum includes agents such as azathioprin, methotrexate or more specific calcineurin inhibitors affecting T-cells and highly selective monoclonal antibodies directed against T-cell subpopulations and other targets. Expand


Topical steroid, cyclosporin A, and the outcome of rat corneal allografts.
The effects of a combination of topical corticosteroid and cyclosporin A on corneal graft survival were tested in a model of penetrating keratoplasty in the inbred rat and the combined formulation caused a reduction in the incidence of rejection which did not reach statistical significance. Expand
Histopathology of rejected orthotopic corneal grafts in the rat.
The results suggest that neither the presence nor absence of DTH responsiveness correlates with the histopathological events that accompany corneal graft rejection, however, preimmunization leads to a different histologic pattern of rejection that is characterized by an intense cellular necrosis. Expand
Evidence that the fate of class II-disparate corneal grafts is determined by the timing of class II expression.
Immunofluorescent stains demonstrated transient expression of class II antigens on graft epithelium after transplantation, which provides a target for rejection in the preimmunized animals but is of insufficient duration to both prime naive animals and provide atarget for antigraft effectors. Expand
Leflunomide, a novel immunosuppressive agent. Transplantation
  • 1993
Update on topical cyclosporin A
Leflunomide in experimental transplantation
  • Transplantation
  • 1994
Efficacy of topically applied leflunomide and cyclosporin A in a model of autoimmune uveitis
  • Dernouchamps JP, Verougstraete C, Caspers-Velu L, Tassig non, eds. Recent Advances in Uveitis
  • 1993
Leflunom - ide , a novel immunosuppressive agent
  • 1993
Leflunomide (HWA 486): A novel immunorestoring drug
  • 1989